Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a report issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.81) per share for the quarter, down from their prior forecast of ($1.64). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.75) EPS, Q3 2025 earnings at ($1.79) EPS, Q4 2025 earnings at ($2.02) EPS, FY2025 earnings at ($7.37) EPS, Q1 2026 earnings at ($1.76) EPS, Q2 2026 earnings at ($1.65) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($6.42) EPS.

A number of other equities analysts also recently commented on AGIO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada lifted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Performance

AGIO opened at $32.38 on Monday. The company has a market capitalization of $1.86 billion, a P/E ratio of 2.86 and a beta of 0.90. The company has a 50-day moving average of $33.80 and a 200-day moving average of $42.28. Agios Pharmaceuticals has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $33,000. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $39,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $53,000. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,587 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.